In a large study analysing the genomes of prostate cancer samples from 930 patients, researchers have found find no fewer than 80 new potential drug targets.

Analysis of prostate cancer mutations identified 11 targets of approved drugs, seven targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials.

Extracting genetic data has become much quicker and cheaper. At the same time, the tools available for handling large datasets have vastly improved. Taken together, this means that the information harvested from the genetic code can be analysed with relative ease.

Once the researchers understood which genes were mutated and potentially causing the cancer, they were able to create a map of the proteins that are coded by the genes. This led them to identify the proteins that were potential drug targets.

According to Cancer Research UK prostate cancer is the most common cancer in males in the UK, with around 47,200 cases (26% of all new cancer cases) in 2015.


E-cigarette key weapon in NHS arsenal, say MPs

E-cigarettes should not be treated in the same way as conventional cigarettes, say MPs.

Aggressive lowering of systolic BP reduces dementia risk

Reductions in the risk of mild cognitive impairment (MCI), and the combination of MCI and dementia, have been shown for...

This website is for healthcare professionals only. By clicking "Accept" to hide this message or by clicking into any content on this website, you confirm you are a healthcare professional, consent to accepting cookies in accordance with our Cookie Policy and agree to Independent Pharmacist’s Terms of Use and Privacy Policy.